Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema

Post author:
Post published:November 28, 2023
Post category:uncategorized

Lead ophthalmology candidate EXN407 has potential to be the first topical treatment for diabetic retinopathy/diabetic macular oedema.

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

Animal research reveals metabolic differences between tirzepatide and semaglutide

New study reveals turmeric and Tinospora Cordifolia reduce liver injury risk in TB patients

Isolation measures during pandemic drove faster, more transmissible SARS-CoV-2 variants, study reveals

Helpful Links

Subscribe To Us